Facts
as of Nov 18, 2026
Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare disease.
It is hiring: 26 open roles, 17 of them posted in the last 30 days.
- Employees
- 201-500estimated range
As of Nov 18, 2026, Alion lists 26 open roles at Travere. The median pay stated in its open roles is $225k, across 27 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring at full speed: most open roles are fresh.
Biotech is the largest family, 24 of open roles.
17Posted in 30 days63% of open roles are fresh
100%Remote roles27 of 27
2Hiring offices
Can they hire you from United States?by your location
Likely
7 open roles are in your country: you apply locally, no move needed.
United States7On site
Switzerland1On site
Remote, from elsewhere46Possible
No posting offers visa sponsorship. Remote roles: 46.
Time to fillmedian days to close a role
Travere68 days
Market, same roles31 days
Alion signals0-100
Demand9
Pay29
Your chance44
How badly they need people, whether they pay, how realistic getting in is.
Open roles over time−100%
Sep 28This week
Open roles a week: 23 then, 0 now
Where the openings areshare of open roles · trend
Biotech24▼
Sales16▲
Leadership14▼
Education11▲
Analytics5▲
HR5▲
Degree asked
Bachelor's Degree 65%Doctoral Degree (PhD) 30%Master's Degree 5%
Experience asked: 8.8 years on average, in 26 postings. 20 postings state a degree.
Benefits named in postingsshare of open roles
Retirement plans26100%
Life insurance26100%
Equity623%
Continuous learning14%
Growth opportunities14%
Contract type
Full-Time 26
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
What its postings pay, by level.
$225kMedianmarket estimate $222k
$195k – $285kTypical rangeUSD a year
$385kHighest paying roleVice President, Regulatory Strategy Diligence
Pay by levelmiddle half of stated pay, median marked · dashed: market median $222k
Senior12$225k$195k – $225k
Head+13$285k$246k – $332k
$0$100k$200k$300k$400k
People cost
Travere filed a median H-1B wage of $136k in 2026.
$136kMedian H-1B wage, 20263 casesSource ↗ $132k–$222kH-1B wage range3 positions
Median H-1B wage by role, 2026scale to $222k
Senior Manager, Commercial Analytics · 1$132k
Associate Director, Pharmacovigilance · 1$222k
Manager, HRIS Operations · 1$136k
Source: the pay stated in the company's postings, normalised to USD a year
Footprint
Hiring in 2 cities in 1 country.
2Cities
1Countries
San DiegoBusiest site
Source: office addresses in postings and company registers
Ranked #7 by open roles among its 11 closest peers.
Source: Alion's similar-companies engine (industry segments, technologies, headquarters country, size)
Public record
Travere in public registers.
Influence
Employees' political contributions, 2026 cycle
2 contributions · their own money, not the company's; names not shown ·
fec.gov ↗$7k
Each line links its register: the agency's page, the EU Transparency Register, the FEC, the USPTO, CourtListener.
Technologies named in job postings at Travere over the last 12 months, by layer, with the share of postings for each.
18Technologies in use
13Postings analysed
69/100Stack modernityAI adopter
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Newsroom
Sep 232026
Blog
The post Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sp…
Sep 232026
News · Pulse 2.0
Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to…
Sep 232026
News · YahooFinance
Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President…
Sep 222026
News · YahooFinance
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today. With th…
Sources: the outlets named on each headline, each story once